Report Summary

The global autoimmune disease diagnostics market was estimated at USD 3520.17 Million in 2017 and is anticipated to gain significant traction over coming years.

The immune system of human body identifies some invaders such as viruses, bacteria, and other exterior foreign substances and attacks those foreign elements to defend the body. Nevertheless, in some cases, the body immune system attacks the healthy cells of the body by considering those cells as foreign materials. Such kind of condition is termed as an autoimmune disease. The autoimmune disease causes atypical tissue growth and deviations in function of the organ. The principal cause of autoimmune development may be the person’s genes with environmental exposure. Currently, there are approximately more than 80 types of autoimmune diseases. Some of the acutest autoimmune diseases are inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. The accurate therapeutic therapy for autoimmune diseases is not accessible yet but only relieving managements are available for this ailments. Nonetheless, diagnosis of the autoimmune diseases can be done by the tests involving complete blood counts, the antibody test, antinuclear antibody test others.

The global autoimmune disease diagnostics market is majorly driven by the increase in the number of people suffering autoimmune diseases. For instance, according to American Autoimmune Related Disease Association (AARDA) reports of 2016, approximately 50 million people suffered autoimmune diseases in the U.S. with around 75% being women. Moreover, rising government initiatives and public consciousness are taken to devote the budget on diagnosis and care services for autoimmune diseases, are another factors which are propelling the global autoimmune disease diagnostics market. Additionally, many of the governments, as well as organizations, are investing in the research and development programs to discover proper care for autoimmune diseases treatments, this factor is expected to help to introduce the new products in the market further augmenting autoimmune disease diagnostics market during the forecast period. For instance, the introduction of novel biomarkers, which has established to be substantial to increase the diagnosis of autoimmune diseases is correspondingly one of the major factor driving the autoimmune diseases diagnostic market.

However, lack of experience and education of laboratory personnel, the lack of the key specialists, slow turnaround time, and high failure of proper outcome rate are some of the major factors restraining the market growth.

Segment Analysis

The global Autoimmune Disease Diagnostics Market is segmented on the basis of type, end user, and geography. On the basis of type, the global Autoimmune Disease Diagnostics Market is segmented into Systemic autoimmune disease diagnostics and Localized autoimmune disease diagnostics. The systemic autoimmune disease diagnostics is further categorized into Rheumatoid arthritis, Ankylosing spondylitis, Systemic lupus erythematosus (SLE), and others. On the other side, the Localized autoimmune disease diagnostics is further categorized into Multiple sclerosis, Type 1 diabetes, Hashimoto's Thyroiditis, Idiopathic thrombocytopenic purpura, and Others. In 2017, Localized disease diagnostics dominated the overall market. The dominance is majorly attributed to the existence of large process measurements and moderately higher patient awareness level in comparison to systemic diseases. On the basis of end users, the global autoimmune disease diagnostics market is segmented into Hospitals, Diagnostics Centers, and Research Laboratories.

Regional Analysis

In terms of geography, North America is estimated to dominate the global autoimmune disease diagnostics market. The dominance is majorly attributed to increasing prevalence of some of the common autoimmune diseases such as type1 diabetes and rheumatoid arthritis. The surge in funding by private and government organizations, growing regulatory scenario observed by World Health Organization (WHO), and advancement in technology are some of the other factors driving the growth of the autoimmune disease diagnostics market in North America. However, the Asia Pacific is expected to be a fast emerging region in the global autoimmune disease diagnostics market. The swift growth is attributed to the increasing incidences of the autoimmune disease, large investments in R&D and surging government support to control the autoimmune disease. the Asia Pacific is expected to dominate the market during the forecast period.

Competitive Landscape

Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Autoimmune Disease Diagnostics Market includes F. Hoffmann-La Roche Ltd, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Inc., SQI Diagnostics, Quest Diagnostics, EUROIMMUN AG, AESKU.Diagnostics GmbH & Co. KG, INOVA Diagnostics, Inc., Crescendo Bioscience, Inc., bioMerieux SA, Bio-Rad Laboratories, Inc., and Hemagen Diagnostics, Inc. among others.